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ABSTRACT
Introduction: Dry mouth or Xerostomia likely affects at least 60 million individuals in USA.
Current management strategies for dry mouth including pharmacological agents, topical
therapies and other non-drug treatments have low quality evidence suggesting limited
effectiveness in alleviating dry mouth symptoms. Patient satisfaction with the wide array of
xerostomia management strategies is not well documented. Furthermore, the impact of
xerostomia as well as use of different management strategies on patient oral health as well as
oral health related quality of life is underexplored.
Objectives: The primary purpose of this study was to evaluate the effect of xerostomia and
satisfaction with dry mouth management strategies on patients’ quality of life. The secondary
purpose of this study was to evaluate patients’ preferences for a new treatment modality, namely
an implantable salivary gland pump, in terms of their willingness to adopt and pay for this
treatment. Variations in willingness to adopt were determined by using perceived quality of life,
satisfaction levels with current therapies, time period since symptomatic with dry mouth, and
other sociodemographic factors, such as ability-to-pay, gender, and education as independent
variables.
Experimental design, methods, and subject population: This study used a survey methodology
to obtain patients’ satisfaction with current xerostomia management strategies, effect of
Xerostomia on their oral and general health, willingness to adopt a new treatment consisting of an
implantable salivary gland pump, and willingness-to-pay out of pocket for the implantable device.
WTP payments are evaluated from two perspectives: 1) initial out-of-pocket payment for moderate
satisfaction with the device; and 2) payment for high to complete satisfaction. Participants had the
option to respond to a paper-based or an online survey. Potential subjects were recruited through
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research flyers displayed at the reception desks of all dental clinics at School of Dental Medicine,
University of Connecticut, and advertisements with a web-link to the survey on all TV monitors
throughout the University of Connecticut Health Center.
Results: A total of 107 individuals responded to the survey through either the paper-based
questionnaire or online survey. Participants (age: 62.28±12.01yr; 48.6% male) had been
experiencing dry mouth symptoms for an average of 9.36±9.29yr (range: 0-48yr). Individuals
with Sjögren’s syndrome and Radiation-related xerostomia had significantly poorer oral healthrelated quality of life when compared to other etiologies of xerostomia (p≤0.0001). A majority of
the respondents (n=73, 68.32%) were either moderately or extremely dissatisfied with dry mouth
management therapies that they were currently using. Lower satisfaction with therapies was also
significantly associated with poorer quality of life (p<0.001). A majority of respondents (55%) were
very or extremely willing to adopt an implantable salivary gland in addition to 29% respondents who
were somewhat willing to adopt the new treatment modality. Respondents’ mean willingness-to-pay
was $2,024 if the treatment provided them with moderate satisfaction. If the treatment provided
high-to-complete satisfaction the mean WTP amount increased to $2,869. Willingness to adopt and
willingness-to-pay for the new treatment were significantly associated with poorer quality of life,
lower satisfaction with currently available dry mouth management strategies, age, number of years
since experiencing dry mouth, amount of money spent monthly on dry mouth management, income,
education as well as presence of a dental implant supported prosthesis (p-values<0.01).

Conclusions: The results of this study suggest that individuals with xerostomia symptoms are
largely dissatisfied with currently available dry mouth management strategies, which negatively
affects their oral health related quality of life. The results of this study indicate that individuals
living with xerostomia would be willing to adopt a dental implant based implantable salivary
gland as a new treatment modality.
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1. INTRODUCTION
1.1. Objective of research
The overall goals of this research study are: 1) to evaluate the effect of xerostomia and
satisfaction with dry mouth management strategies on patients’ quality of life; and 2) to evaluate
patients’ preferences for a new treatment modality, namely an implantable salivary gland pump,
in terms of their willingness to adopt different surgical and prosthetic phases of this treatment
as well as their willingness-to-pay for this treatment.

1.2. Review of literature and scientific background
1.2.1 Xerostomia: etiology and epidemiology overview
Definition: Xerostomia, also known as dry mouth, is a subjective term used to describe the
sensation of dryness, which is commonly but not always associated with salivary gland
hypofunction or hyposalivation.1-3 The latter is an objective measure defined as stimulated
salivary flow rate ≤0.5–0.7 mL/min and unstimulated salivary flow rate ≤0.1 mL/min.1 In
comparison, normal stimulated salivary flow rate averages 1.5–2.0 mL/min while the
unstimulated salivary flow rate is approximately 0.3–0.4 mL/min in a healthy individual.4
Interestingly, many patients with hyposalivation have no complaints of xerostomia. The
converse is also true and many patients with xerostomia complaints have normal salivary gland
activity.1, 5, 6 This may be due to altered visco-elastotic properties of the saliva that may fail to
lubricate the mouth properly, or due to patients’ altered perception mechanism.3, 7
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1.2.1.1 Etiology
Various causes have been implicated in the diagnosis of xerstomia, including: 1) diseases and
infections, 2) side effects of radiotherapy, radioisotopes and transiently in chemotherapy, 3)
medication-induced, 4) physiologic, and 5) psychogenic causes.
Diseases and infections: One of the most common medical conditions associated with dry
mouth includes Sjögren’s syndrome, which is a multisystem autoimmune and chronic
inflammatory disease that results in infiltration of lymphocytes in exocrine glands, including
salivary and lacrimal glands, resulting in its distinctive features of xerostomia and dry eyes.8
Other diseases and infections associated with Xerostomia include: 1) Salivary gland aplasia or
agenesis, 2) autoimmune and inflammatory primary biliary cirrhosis, 3) granulomatous diseases
such as sarcoidosis, 4) amyloidosis, 5) immunoglobulin G4–related sclerosing disease, 6) graftversus-host disease, 6) lymphoma, 7) type 1 and 2 diabetes, and 8) HIV/AIDS and hepatitis C
infections.9, 10 11
Radiotherapy, radioisotopes and chemotherapy: Xerostomia is the main side effect of standard
fractionated external radiation therapy (RT) to the head and neck region. Acute xerostomia
results from an inflammatory reaction and has an early onset with nearly half the patients
presenting with decreased salivary flow within the first week. The severity of the condition
depends on the radiation dosimetry and the treatment duration. 12 Salivary flow can diminish up
to 20% after 7 weeks of head and neck RT. Late xerostomia, which can occur up to one year
after RT results from fibrosis of the salivary glands and is usually permanent.8, 12, 13
In addition, internal radionuclide therapy with radiolabeled antibodies and bone-seeking
radiopharmaceuticals for malignant lymphoma as well as use of radioactive iodine (I-131) for
thyroid cancer patients has also been associated with Xerostomia.8, 14-16
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Chemotherapy causes transient xerostomia by making the saliva thicker and can last for 2-8
weeks after completion of treatment.
Medication induced: Drugs implicated in Xerostomia can be broadly categorized into the
following: anticholinergics/antimuscarinics, antihistamines, antihypertensives, antidepressants
and antipsychotics, hypnotics, phenothiazines, sedatives, anginals, antiasthma drugs, diuretics,
thyroxine, skeletal muscle relaxants, psychiatric drugs, iron supplements, narcotic analgesics,
daily aspirin, highly active antiretroviral therapy (HAART).8, 9, 11, 17, 18 A detailed list of drugs
known to be associated with xerostomia is presented in Table 1.
A higher prevalence of self-reported xerostomia has been reported with a higher number of
medications used by individuals.19
Physiologic and psychogenic causes: Dehydration and mouth-breathing may add to the
perception of oral dryness. Furthermore, neurological or psychological disorders and affective
(mood) disorders may affect the autonomic nervous system and such individuals may experience
xerostomia.9, 20-22
1.2.1.2 Prevalence
Despite many epidemiological reports, the true population prevalence of xerostomia is not
known and reported estimates range from 0.9% to 49%.5, 6, 19, 23-25 The variability exists due to
epidemiological issues and limitations in measuring the condition itself.26 These include study
design, sampling and statistical power issues as well as inadequacy of case definition and
measurement of dry mouth, and the selection and measurement of relevant exposure measures,
including potential confounding variables such as medications.26
A conservative estimate of approximately 20% in the general population has been proposed,6
which translates to approximately 63.78 million individuals in USA based on 2014 population.
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Age and gender stratification indicates much higher prevalence in women (20-46%) compared
to men (13–26%) as well as in the elderly (up to 50%).5, 6, 19, 24, 25 In a longitudinal study, the
prevalence of xerostomia increased from 6% at 50 years of age to 15% at 65yrs of age.27
In the United States, Hochberg et al. (1998) estimated 17.2% prevalence (Men- 13.2; Women
20.1) in the elderly population ranging from 65-84years old.28 As reported by Sjögren’s
Syndrome Foundation, more than 4 million people are living with Sjögren’s Syndrome in the
United Sates, with 90% of them being women (ref). In other disease-specific studies, 30-40%
patients with HIV have reported xerostomia,11, 29 which would account for half a million people
in USA with HIV-related Xerostomia. Furthermore, studies have reported that 50-75%
individuals with diabetes type 1 and 2 experience Xerostomia,30-32 which translates into nearly
20 million people living with this condition in USA. A gross estimation of the distribution of
Xerostomia in USA is detailed in Table 2.
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Table 1. Drugs implicated in Xerostomia*
Anticholinergics/antimuscarinics

Atropine, belladonna, benztropine, oxybutynin, scopolamine,
trihexyphenidy
Antihistamines
Astemizole,
brompheniramine,
chlorpheniramine,
diphenhydramine, loratadine, meclizine
Antidepressants and Antipsychotics
Selective serotonin-reuptake inhibitors: citalopram, fluoxetine,
paroxetine, sertraline, venlafaxine
Tricyclic antidepressants:, amitriptyline, desipramine, nortriptyline
Heterocyclic antidepressants: imipramine, haloperidol, mirtazapine
Monoamine oxidase inhibitors IMAO: pimozide
Atypical (second generation) antipsychotics: phenelzine, clozapine,
olanzapine, bupropion, nefazodone,
Antihypertensives
Captopril,
clonidine,
clonidine/chlorthalidone,
enalapril,
guanfacine, lisinopril, methyldopa
Anxiolytic and sedatives
Alprazolam, diazepam, furazepam, temazepam, triazolam
Skeletal muscle relaxants
Cyclobenzaprine, orphenadrine, tizanidine
Diuretics
Chlorotiazide, furosemide, hydrochlorothiazide, triamterene
Opiod analgesics
Central nervous system: codeine, meperidine, methadone,
pentazocine, propoxyphene, tramadol
Nonsteroidal anti inflammatory
Diflunisal, ibuprofen, naproxen, piroxicam
Miscellanous
iron supplements
thyroxine
Anorexiants: diethylpropion (amfepramone), sibutramine
Antiacne agents (retinoids): isotretinoin
Anticonvulsants: carbamazepine
Antidysrhythmics: disopyramide
Anti-incontinence agent -anticholinergics-: tolterodine
Antiparkinsonian agents: carbidopa / levodopa
Bronchial dilators-anticholinergics-: ipratropium
Ophthalmic formulations: brimonidine (alpha-2 adrenergic
agonist)
Smoking cessation agents: nicotine
Adrenergic agents: Amphetamine
Drugs of abuse: MDMA, cannabis
Highly active antiretroviral therapy (HAART)
17
* Sources: Guggenheimer et al. , Miranda-Rius et al.8
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Table 2. Estimation of Xerostomia distribution by etiology in USA
Source
estimation
Total number of Xerostomia patients in
USA

Sjögren’s Syndrome related Xerstomia

Diabetes related Xerostomia
(Prevalence of Diabetics in USA=
29.1million. Source: American Diabetes
Association)
HIV related Xerostomia
(Prevalence of HIV in USA- 1.2million.
Source: CDC)
Head and neck cancer radiationinduced Xerostomia
- Prevalence of HNC in USA- 300,682;
Source: NCI SEER 2013)
- Approximate no. of patients
undergoing
radiation
therapy
with/without chemothapy33 = 63%
Thyroid cancer radioactive iodine (RAI)
related Xerostomia
- Prevalence of Thyroid cancer in USA637,115; Source: NCI SEER 2013)
- Average no. of patients undergoing
RAI therapy= 80-100% 37-39
Drug-Induced, Age-related, and other
causes

of

Conservative
estimate of 20% of
total
US
6
population
Sjögren’s
Syndrome
Foundation
50-75% patients
with Type 1 and 2
DM30-32

Estimation of number
of individuals with the
condition
63.78 Million

4 Million

14.5-21.8 Million

30-40% patients
with HIV11, 29

360,000-480,000

30-100% patients
with radiation34-36

56,800-189,400

15-60%36, 40

76,450- 383,000

37.4- 44.8 Million

6

1.2.2 Impact of xerostomia on oral health and oral health related quality of life
Individuals with xerostomia often complain of problems with eating, speaking, swallowing and
wearing dentures. Denture wearers have problems with denture retention, denture sores and the
tongue sticking to the palate. Xerostomia has also been associated with taste disorders
(dysgeusia) and painful tongue (glossodynia). ADA Council on Scientific Affairs (2015)
reported specific clinical signs and symptoms within the oral cavity associated with
hyposalivation (Table 3).
In addition to the physiological effects of Xerostomia, people living with this condition
experience severe negative psychosocial sequelae. Oral health related quality of life studies in
the elderly have shown significantly higher levels of psychological stress, difficulty relaxing,
inability to carry out regular function, lower levels of satisfaction with life, feeling selfconscious and tense all the time, difficulty doing usual jobs and social embarrassment while
eating from having to interrupt meals. Even in younger adults and adolescents living with type
1 diabetes, there is a strong correlation between xerostomia and poorer quality of life, with the
most prominent implant being self-consciousness, embarrassment and discomfort while
eating.13, 30, 32, 36, 41-53
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Table 3. Signs and symptoms associated with hyposalivation

Teeth

Oral Mucosa

Tongue

Lips

Others

Increased incidence of tooth decay
Enamel demineralization (chalky spots at the cervical regions of the teeth)
Enamel erosion and attrition
Increased plaque accumulation
Increased tooth hypersensitivity
Mucositis
Mucosal desquamation
Atrophic mucosa
Allergic or contact stomatitis and lichenoid lesions (mostly opposing metal
restorations)
Recurrent oral candidiasis
Traumatic ulcerations on the lateral border of the tongue, the buccal
mucosa or both
Painful or burning mouth (intolerance to spicy, sour or salty food and
drinks)
Nonspecific gingival inflammation and generalized oral erythema
Dryness, fissuring, lobulation
Atrophy
Erythema
Loss of papillae
Crenulations on tongue (scalloped borders)
Dryness, chapping
Peeling
Fissuring
Angular cheilitis
Oral allergic or contact reactions
Halitosis
Difficulty talking, chewing or swallowing (dysphagia)
Plaque accumulation
Reduced oral clearance
Altered taste sensation (dysgeusia)
Food retention and debris on the teeth, tongue or along gingival margins
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1.2.3 Management of xerostomia
Interventions specific to treatment of hyposalivation include: 1) pharmacologic treatment with
salivary stimulants (sialogogues); and 2) palliative measures to improve salivary output, such as
using sugar-free salivary stimulants (e.g., chewing gum). However, a multidisciplinary approach
to initial management of dry mouth tailored for each patient has been recommended by ADA.
This should include palliative care, patient education, management of medical condition or
medication, and preventing oral complications.8
Sialogogues: These drugs stimulate salivary secretion by acting on systemic receptors,
including: a) direct and indirect muscarinic agonists, b) peripheral adrenergic α2 antagonists,
and c) centrally active agents that diminish adrenergic tone.8 Pilocarpine hydrochloride,
marketed as Salagen, is one of the most commonly used sialogogic drugs and has been shown
to have some effectiveness in Xerostomia related to Sjögren syndrome and radiation therapy
with bone marrow transplantation.54-57 However, a recent Cochrane review concluded that the
evidence to support pilocarpine hydrochloride in the treatment of radiation-induced xerostomia
was limited.58 In addition, Cevimeline Hydrochloride has been indicated for individuals with
Sjögren syndrome.57 Bethanechol chloride has been reported to reduce the xerostomia effect
caused by antidepressants and antipsychotic medications.59, 60 Anetholetrithone is another drug
with empirical evidence that shows improvement in xerostomia. Other sialogogic drugs that
have been proposed but have little scientific evidence include bromhexine, mucolytic agents
such as guaiphenesin, neostigmine, distigmine, yohimbine, nicotinic and malic acid.8
Response to sialogogic drugs could vary based on the amount of healthy acinar cells in the
salivary glands. In summary, the effectiveness of sialogogic drugs is limited and comes mostly
from low quality evidence.58 Moreover, these agents themselves have many secondary adverse
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effects including, but not limited to, gastrointestinal alterations, sweating, bronchospasms,
altered heart rate and blurred vision.8
Immunologic modulators: Another emerging category of pharmaceutical agents that have been
purported for use in xerostomia patients include substances that control immunologic response,
and function by aiding tissue regeneration of salivary glands. Therefore, these are used for tissue
auto-immune related xerostomia, such as Sjögren syndrome.61

Interferon alpha (IFN-α),

Rituximad and Amifostine are immunologic an cytoprotective agents with some empirical
evidence on effectiveness. Other proposed agents with little to no scientific evidence include
anti-tumor necrosis factor alpha therapy (etanercept, abatacept, infliximab, adalimumab,
certolizumab pegol, and golimumab),

hydroxychloroquine, anti-inflammatory drugs,

methotrexate, hormone replacement, and other monoclonal antibodies.8, 55, 56
Palliative topical therapy: Numerous over-the-counter products for dry mouth, including
mouthwash, oral patches, rinses, lozenges, toothpastes, sprays, gels, and chewing gums are now
marketed. These agents function as salivary substitutes, local-acting salivary stimulants, and
lubricants. However, they do not provide the protective function of saliva. Also, their duration
of effect is usually short and lasts for the time the agent in present in the oral cavity.
Despite the number of topical agents, there is no consensus on the comparative effectiveness of
these products in relieving dryness. A Cochrane review published in 2011 on topic therapies for
dry mouth concluded that there was no strong evidence in support of any of the available topical
products in alleviating the symptoms of xerostomia.6 Within the category of sprays, oxygenated
glycerol triester saliva substitute spray was found to be more efficacious than an electrolyte
spray.6 Also, the use of salivary stimulants, such as sugar-free chewing gum, has been found to
be more successful than salivary substitutes in patients with residual salivary function. 8, 62
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Intra-oral devices which act as reservoirs have been developed to prolong the period of
availability of the topical agent in the mouth.63-66 These reservoirs can also be constructed as
part of the patient’s prosthesis. However, these have low success rates.8
Acupuncture: This modality has been proposed to have a physiological and psychological effect
on xerostomia through activation of biological mechanisms; however, the evidence is low
quality as reported by a Cochrane review and the observed efficacy in some studies may be
attributed to a placebo effect.24
Neuroelectric stimulation: Transcutaneous Electrical Nerve Stimulation (TENS) and other
neuroelectric stimulation have been tried but have inadequate evidence on efficacy. 24
Regenerative methods: Researchers are currently evaluating gene therapy and stem cell
transplantation in human salivary glands, which has shown potential in improving salivary
secretion.67
Herbal medicine: Jaborandi, betel nut, citric acid, red pepper, bakumondoto, Iceland Moss and
Longo Vital have been proposed to stimulate salivary secretion, but have limited evidence on
effectiveness.8
1.2.3.1 Artificial salivary gland pump- product in development
The PI is involved in development of a prototype artificial salivary gland pump, which will be
a dental implant-like implantable medical device. A dental implant is an artificial tooth root like
structure commonly made of titanium. This dental implant like device will be placed into the
patients’ upper or lower jaw bones by a surgical procedure and a crown will be placed on it to
replace the missing tooth. This implant will have an internal component in the form of a pump
which will be driven by tooth contact and masticatory forces, to harvest interstitial fluid and
treat it via ion-exchange resin chemistry as a continuously available saliva replacement. The
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function of this internal pump will be maintained for 1 year after which it will need to be replaced
in a dental office. This device may be used in patients who have all teeth or are missing a few
teeth but may not be used for completely edentulous patients at the current stage of its
development.

1.2.4 Assessing patient preferences for artificial salivary gland pump
Decision to uptake a new healthcare technology or intervention either at an individual or at a
societal level depends upon the perception of both clinical and economical effectiveness of one
intervention over another.68-71 Clinical effectiveness studies provide a measure of the expected
change in health outcomes. Additionally, cost-effectiveness studies provide incremental costs
per increment of benefit associated with an intervention outcome.72, 73 However, neither of these
studies capture patients’ appraisal of the outcome, or in other words a patient’s preferences.
Preference-based evaluations are increasingly being considered important in technology
diffusion74, 75, especially in privately financed dental care where economic resources are limited.

1.2.5 Measuring preferences
Preference measurement requires categorizing health states based on the interventions under
comparison, followed by measurement of an individuals’ strength of preference for each health
state.76 There are various direct and indirect methods of measuring preferences. Commonly
used methods of measuring preferences directly include rating scale and its variants such as
visual analogue scale, time-trade-off method, and standard gamble techniques.72, 76 Indirect
methods are used to measure overall health related quality of life (HRQoL) and include generic
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preference instruments (such as the Short form-6 dimension (SF-6D) and health utility index
(HUI) instruments) and disease-specific preference measures from a disease-specific healthrelated quality of life instrument to a generic instrument.72, 76, 77
Oral health related quality of life (OHRQol): Another commonly used method of impact
assessment in dentistry is oral health related quality of life (OHRQol) which are self-reports that
capture functional, social and psychological impacts of oral disease.78 These measures can be
used to compare outcome of different interventions or before-after intervention outcomes.
However, they are based on scaled indices that can measure the impact of an intervention on a
particular outcome (e.g. chewing before and after intervention) but do not include an individual’s
assessment of the effect of this particular outcome on their well-being. Therefore, these
instruments cannot be considered as direct preference measurement tools.

1.2.6 Willingness-to-pay as a Preference Measurement Method
The foundation of willingness-to-pay (WTP) studies is based on the concepts of normative
welfare economics. ‘Welfare’ is a term used to describe an individual’s ‘well-being’ resulting
from consumption of goods and services. Welfare measures are simply changes in individual’s
preferences converted into monetary terms.79 Economic evaluations in health care based on the
theory of welfare economics depend upon assessment of welfare change due to health
interventions or adoption of new technology. This allows comparison between the value of what
individuals would benefit (welfare gain) from any health care intervention and the value of the
resources that individuals are ready to trade-off (e.g. costs).
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1.2.4.1.2 Overview of the willingness-to-pay method
This preference measurement method uses a survey-based approach to elicit individual’s
willingness-to-pay (WTP) for specific gains/losses in their health following an intervention.72,
75, 79, 80

Respondents are presented with hypothetical scenarios and are asked to assume health

benefits from the intervention under evaluation. Under the contingency of these health benefits,
the respondents are asked to state the maximum monetary value that they would be willing to
pay for such benefits.72, 79, 80
The benefits of using a WTP method over other preference measurement instruments are that it
incorporates uncertainty associated with the outcome and allows an individual to value overall
consequences of a health technology not restricted to health outcomes.72 Moreover, the monetary
approach of a WTP methodology is highly representative of the way individuals respond to
health intervention decisions (particularly in countries in which health care is privately paid) and
provides benefit measures that are directly comparable to the costs of the intervention. Economic
evaluations that use a monetary approach to measuring benefits are known as cost-benefit
analyses72, 79.
1.2.4.1.3 WTP Survey Design
Population and sampling: The initial step in designing a WTP survey is identification of the
target population that would benefit from the health care intervention. While it may be argued
that patients are the principal population that will benefit from an intervention, societal
preferences are increasingly being sought in economic evaluations. This arises from the pretext
that health care costs, such as private insurance and tax-funded programs, are distributed
amongst people who are direct beneficiaries and those who are not 79, 81-83.
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After defining the population to be surveyed, a representative sample needs to be selected.
Sample selection is crucial because the responses obtained from the sample will determine the
preferences of the surveyed population towards the intervention. Moreover, accurate sampling
reduces the incidence of sampling biases, such as sample selection bias and sample frame bias.
Sample selection bias occurs due to non-response and results in different values obtained from
respondents compared to non-respondents. Sample frame bias occurs when the sample drawn
from the population differs from the population itself 80.
Mitchell and Carson 80 have indicated two principal methods of sample selection that increases
the reliability of the WTP sample: 1) use of a sufficiently large sample, and 2) use of statistical
techniques that reduce the influence of outliers. Large sample sizes ensure the precision of WTP
measures such as the mean WTP amount, given the large variance expected from a
heterogeneous population.80
Scenario Design: The four essential components of a well-designed WTP scenario include: 1)
a detailed description of the intervention under the hypothetical context that is presented to the
respondents, 2) risk communication, 3) payment vehicle and 4) elicitation method.
Defining the intervention/service being valued: Apart from uncertainty in health outcomes
from an intervention, a general population represents uncertainty in need. Interventions can be
described from different perspectives based on the uncertainty in need as: 1) certain need (expost perspective) in the case of patients suffering from the disease, and 2) uncertain need (exante perspective) in case of potential patients.72, 79, 80. For instance, an implanted device to
produce saliva can be described from an ex-post perspective for elderly patients with Xerostomia
and from an ex-ante perspective for the middle-aged population, the potential patient pool.

15

Risk Communication: Due to the complex nature of the WTP method to value a health
intervention, the scenario should provide a meaningful and comprehensible description to
overcome the hypothetical character of the scenario. It is important to consider that a respondent
may not be familiar with the intervention being valued in the survey. Therefore, it is crucial to
provide all relevant information about the different attributes of the intervention to ensure a
correct scenario description.72, 79, 80
In addition, a scenario might include probabilities of uncertainty with respect to the need and
the outcome of the intervention. Gigerenzer84 suggests that absolute, rather than relative, risk
should be used for proper risk communication, either as probabilities (such as: 1 in 100) or
absolute frequencies (such as: 5000 children affected per year).
Payment Vehicle: The payment vehicle denotes the type of payment a respondent is being asked
to make. These may include additional income taxes, private insurance premiums, charitable
donations, paying ‘out-of-pocket’, etc. 72, 79, 80 The choice of the payment vehicle depends on the
scenario description.79 For instance, insurance premiums and additional taxes best describe an
uncertain need and are used from an ex-ante perspective. On the other hand, an ex-post
perspective describing a certain need may elicit ‘out-of-pocket’ payments.
The timing of the payments is equally important and should be well-defined in the scenario.
Respondents may be asked to provide their maximum WTP either as a one-time payment or in
stages, as monthly or yearly payments.79
Elicitation Format: The elicitation format represents the technique of questioning to obtain
WTP amounts. There are various formats, each with its strength and weaknesses. 79, 80 The choice
of the elicitation format is essential since the questioning method has been shown to significantly
influence the mean and median estimates WTP values. 85, 86 These include discrete choice versus

16

continuous elicitation methods. As the name suggests, continuous methods include a range of
monetary values that a respondent can choose from. In comparison, discrete choice questions
provide a discrete bid amount leading to a yes/no response.

1.3. Study rationale
Dry mouth or Xerostomia affects at least 60million individuals in USA (see section 2.1.3 for
details). Current management strategies for dry mouth including pharmacological agents, topical
therapies and other non-drug treatments have low quality evidence suggesting limited
effectiveness in alleviating dry mouth symptoms.6, 58, 87, 88
Patients’ utilization and satisfaction with the wide array of xerostomia management strategies is
not well understood. Most studies compare single treatment strategies to a placebo or no
treatment. However, anecdotal evidence indicates that most patients try a plethora of strategies
with diverse satisfaction. Furthermore, the impact of xerostomia as well as use of different
management strategies on patients’ oral health as well as oral health related quality of life is
underexplored. This survey-based study incorporates items on the above-mentioned knowledge
gaps to better understand patient satisfaction with existing therapies and association with oral
health and quality of life. In addition, it will provide valuable information on how willing
patients are to adopt a new treatment modality, namely the artificial salivary gland pump.
As discussed previously, diffusion and adoption of costly and sophisticated health care
technology/interventions such as implantable salivary glands depend not only on its clinical
effectiveness. As costs of such therapies may be mostly borne by private payers, either out-ofpocket or as insurance, the demand for a new technology intervention is highly contingent on
the individuals’ perception of its benefits. Such preferences for the new salivary gland pump can
be of tremendous value to stakeholders in assessing its future demand.
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Willingness-to-pay surveys measure individuals’ preferences in monetary terms. This study was
designed to elicit individual’s WTP for an implantable salivary gland pump using two
hypothetical constructs, namely, out-of-the-pocket payments for an implantable pump that will
provide patients with: 1) moderate satisfaction, and 2) high to complete satisfaction. The
preference aspect of this study was specifically designed to elicit additional monetary evidence
such that it would be valuable to stakeholders, such as dentists, insurance companies and
manufacturers of the device. Furthermore, WTP results are a necessary first step in conducting
a cost-benefit analysis for a healthcare service. This analysis will be informative to policymakers if an insurance-based funding strategy is considered for this implantable device in future.

1.4. Specific aims and hypotheses
Aim 1a: To evaluate the effect of xerostomia on patients’ quality of life.
Summary: Section 1, Question 2 assessed oral health-related quality of life using 15 items in 4
domains, namely, physical functioning, personal/psychological functioning, social functioning,
and pain/discomfort issues.
Aim 1b: To evaluate the differences in quality of life among different causes of Xerostomia.
Null Hypotheses: There is no difference in the quality of life scores (total average and domain
averages) amongst different sources of Xerostomia.
Aim 2a: To assess the various techniques/medications that xerostomia patients have
previously tried or are currently using.
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Summary: Section II, question 3 elicits information on various techniques and medications for
management of xerostomia in terms of whether the Xerostomia patients are currently using
one/more of these.
Aim 2b: To evaluate xerostomia patients’ satisfaction with currently used therapies.
Summary:

Section

II

question

4

elicits

individual’s

overall

satisfaction

with

techniques/medications that they are currently using for dry mouth condition.
Aim 2c: To evaluate differences in satisfaction with currently used therapies among
different causes of Xerostomia
Null Hypothesis: There is no difference in the level of satisfaction with current therapies
amongst different sources of xerostomia.
Aim 3: To assess the impact of satisfaction with currently used therapies on Xerostomia
patients’ quality of life.
Hypothesis: Individuals with overall lower levels of satisfaction with current therapies will have
a poorer quality of life (higher score on Item 2).
Aim 4a: To assess xerostomia patients’ willingness-to-adopt an implantable salivary gland
pump as a treatment modality for their dry mouth symptoms.
Summary: Section III, Questions 5 and 6 sequentially assessed individuals’ willingness to adopt
new treatment on a 1-5 scale (not at all, not very, somewhat, very, extremely willing).
Aim 4b: To assess xerostomia patients’ willingness-to-pay for an implantable salivary
gland pump as out of pocket payments for i) moderate satisfaction; and ii) high to complete
satisfaction as treatment outcome.
Summary: Section III, Questions 7 and 8 elicit out-of-pocket WTP.
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Aim 4c: To assess variations in: i) willingness to adopt the implantable salivary gland, and
ii) willingness-to-pay amounts with perceived quality of life, satisfaction levels with current
therapies, period since symptomatic with dry mouth, and other sociodemographic factors,
such as ability-to-pay, gender, and education.
Hypotheses: 1) Higher willingness to adopt the implant salivary gland and higher willingnessto-pay amounts will be associated with: a) poorer quality of life; b) lower levels of satisfaction
with current therapies; c) longer period since symptomatic with dry mouth; d) higher ability-topay (income); and e) higher education.
2) There is no association between willingness to adopt and WTP amounts and: a) etiology of
Xerostomia; and b) gender.
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2. METHODS
2.1. Overview of study design
This study used a survey to obtain patients’ satisfaction with current xerostomia management
strategies, effect of Xerostomia on their oral and general health, willingness to adopt a new
treatment consisting of an implantable salivary gland pump, and willingness-to-pay out of
pocket for the implantable device. WTP payments were evaluated from two perspectives: 1)
initial out-of-pocket payment for moderate satisfaction with the device; and 2) payment for high
to complete satisfaction. Additional yearly payments were fixed for both perspectives.
The survey was carried out using paper-based and online surveys; data collection extended from
August 2017 to May 2018.

2.2. Survey sampling
The source population of the study comprised of patients experiencing Xerostomia due to any
cause reviewed in the previous sections, namely: medication-induced; disease and infections;
side effects of radiation therapy, radioisotopes, chemotherapy; Sjögren’s syndrome and other
autoimmune conditions; and physiologic and psychogenic causes. The general inclusion criteria
for study are: 1) presence of subjective xerostomia; 2) use of at least one therapy/medication for
treatment of xerostomia as listed in the questionnaire; 3) 18 years or older; 4) dentate or partially
edentulous individuals; and 5) able to understand English and respond to paper-based/online
questionnaire. Exclusion criteria include: 1) subjects who are unable to independently complete
the questionnaire.
Recruitment of potential respondents was carried out using flyers displayed at the reception
desks of all dental clinics at the School of Dental Medicine (SDM), University of Connecticut
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Health Center. The research flyer with a web-link to the online survey was also displayed on all
TV monitors across UConn Health.

2.3. Survey Instrument
2.3.1 Survey technique
The survey was administered as: 1) a paper based hard- copy questionnaire, or 2) a web-based
survey, based on the participants preferred mode of response.
The web-based survey was designed using Survey MonkeyTM, which is an online survey tool
hosted in USA that allows data privacy and security as well as anonymous responses. A oneyear pro-plan was purchased that allowed advanced question formats and customizable
publishing settings. The content and structure of the online survey was the same as that of the
paper-based questionnaire.
Paper-based questionnaires were made available at the reception desks of SDM dental clinics
for the potential participants to complete. The questionnaire was enclosed in a sealable return
envelope with printed address and a sticker on the back indicating to the respondent that he/she
must seal the envelope prior to returning it to the front desk. Respondents will be asked to not
include their name or other identifiers anywhere on the questionnaire or return self-stamped
envelope. IRB approval for dispersal of a total of 249 surveys was obtained. Completed surveys
were collected bi-weekly and new questionnaires were made available keeping a total count of
dispersed questionnaires for response rate calculation.
2.3.2 Survey design
The survey was collected information in an anonymous manner, therefore, a separate informed
consent letter was not provided to the participants. A cover letter (see Appendix 1) was included
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with each paper-based and web-based survey, which included: a) Name, number and email of
the study coordinator to contact if the subject has questions; b) a brief description of the study
purpose; c) a brief description of the content of the survey; d) a statement that participation is
voluntary; e) a statement that subjects may skip any questions they wish to, for any reason; f)
explanation that choosing to not participate will not affect any services which the respondent is
receiving at the study site or for which s/he would otherwise be eligible; g) confidentiality
considerations; and h) statement that participation in the survey implies consent.
The survey instrument titled: “Dry mouth treatments” is attached in Appendix 1.
The survey included questions that provide essential information that is largely lacking in
published literature. Section I included questions that elicit the cause of the participants’ dry
mouth and the effect of dry mouth on their quality of life. Section II aimed to understand
participant’s satisfaction with currently available treatment options. Section III elicited
willingness-to-adopt an implantable salivary gland pump and willingness-to-pay for it by outof-pocket. This section provides information to the study team with respect to individuals’
preferences for new treatment and is crucial for product development. Section IV elicits
Sociodemographic information from the respondents. This information is important to be able
to understand the relation between particular groups of Xerostomia patients and their quality of
life, satisfaction with current therapies as well as willingness to adopt new treatment.
The survey included multiple choice questions (Section I, Question 1 1; Section 4, Item 1, 4 and
5), Likert rating Scales (Section I, Question 2; Section II, Question 1; Section III, Question 1, 2
and 3), payment card scales (Section III, Question 4 and 5), and open ended questions (Section
IV, Questions 2 and 3).
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The survey questionnaire was designed by the study coordinator and PI. The questionnaire was
reviewed by various experts in the field for construct validity of the instrument: Prof. Jocelyne
Feine, Dr. James Grady, Dr. Martin Freilich, Dr. Rob. Aseltine and Dr. Richard Stevens, prior
to submission for IRB. The questionnaire was also presented and modified based on suggestions
at the graduate student’s protocol defense by Dr. Robert Kelly, Dr. Avinash Bidra, Dr. Martin
Freilich, Dr. Rob. Aseltine, and Prof. Jocelyne Feine.
A pilot survey with 2 patients was carried out to establish content and theoretical (construct)
validity of the survey questionnaire as well as assess the feasibility of conducting the survey
with a larger sample size.

2.4. Ethical Considerations
Prior to the start of the study, ethical approval was obtained from the University of Connecticut
Health Center Institutional Review Board in July 2017 (study ID: 17-016-2).
For the internet-based surveys, the purchased Survey Monkey ADVANTAGE plan allowed
various privacy and security features to be enabled: 1) the survey could not be indexed by search
engines, 2) the survey was made anonymous by hiding invite codes, email address of
respondents, custom invite variables, referring URL, get parameters, IP address of the
respondent and the username if the user was logged in. Furthermore, only users with a valid
unused link were able to take the survey. This ensured that multiple responses were not
generated by the same individual.
For any personal questions in the questionnaire that the subjects may feel uncomfortable
answering, we included a “I prefer not to answer” option.
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2.5 Data Management
The data collected using the online survey was downloaded into an excel sheet and then exported
to Statistical Package for the Social Science (SPSS), version 25.0.0 for Windows, IBM SPSS
Statistics. Data from paper-based questionnaires was manually entered into SPSS and rechecked
for reliability of data entry. Prior to data analysis, value labels were assigned to each variable
based on the questionnaire. Preliminary assessment including frequency analysis was done to
assess the data for missing values and inconsistencies. The errors were verified by reexamination of the raw data in the paper-based questionnaires where appropriate.

2.6 Data Analysis
2.6.1 Variables
Outcome and explanatory variables were defined for each specific aim.
2.6.1.1 Categorical, ordinal and interval variables
Etiologies of Xerostomia (Section 1, question 1) were elicited as 8 categories: Sjögren’s
syndrome, Diabetes, Medication induced, Radiation induced, Radioactive iodine for thyroid
cancer, Age-related, Other, and I do not know. However, several respondents marked multiple
answers and these categories could not be considered mutually exclusive. Therefore, each
category was coded as a dichotomous (categorical) variable with Yes/No responses.
Dry mouth management strategies (Section 2, question 3) included a) sipping water/liquids,
b) candies, cough lollies, chewing gums, c) over the counter medications and d) others.
Respondents were asked to mark all management techniques that they currently use as well as
to specify other strategies. Management strategies were coded as categorical variables with
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dichotomous (yes/no) responses as the categories were not mutually exclusive and several
respondents used more than 1 therapy.

Level of satisfaction with current therapy (Section 2, question 2), was elicited on a 1-5 scale
of satisfaction (Extremely dissatisfied, Moderately dissatisfied, Neutral, Moderately satisfied,
Extremely satisfied); higher scores represented better satisfaction. Satisfaction level was treated
as an interval variable for inferential analyses.

Willingness to adopt (Section 3) an implantable salivary gland (question 5) was coded as an
ordinal variable on a 5 point scale (not at all, not very, somewhat, very, extremely willing) with
higher scores representing higher willingness to adopt. Similarly, willingness to adopt an
implant salivary gland with a yearly replacement of internal component (question 6) was elicited
in the same format and coded as an ordinal variable.

Annual household income (Section 4, question 15) was preferred over individual income
measures since it better represents the availability of financial resources. Annual household
income, hereinafter referred to as ‘income’, was recorded using the following categories: less
than $25,000, $25,000-$50,000, $50,000-$75,000, $75,000-$100,000, more than $100,000.
Categorical responses were obtained, rather than precise income amounts, due to sensitivity
issues with income-related questions.89

Additionally, sex (male/female), presence of prosthesis in mouth (denture/partial denture/dental
implant), highest level of education (primary school or less, high school, college, university,
graduate university or higher) were coded as categorical variables.
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Categories within each variable with limited number of responses were merged for descriptive
and inferential analyses, for instance, education categories were merged from 5 categories to 3
categories (high school or less, college/university, and graduate university or higher).

2.6.1.2 Continuous variables
Oral Health-related Quality of life
Section I, question 2 of the survey includes a modified version of University of Michigan
Xerostomia-Related Quality of Life Scale (XeQOLS), which includes four major domains of
oral health-related quality of life: physical functioning (items nos. i, vi, ix and xiii),
personal/psychological functioning (items nos. ix, xiv and xv) , social functioning (item Nos. iv,
v, xii), and pain/discomfort issues (items Nos. ii, iii, vii, viii, x). Item nos. xiv and xv were added
to the questionnaire for their pertinence to oral health, are were included in the
personal/psychological functioning domain for data analysis.
Responses include frequency of symptoms (never, rarely, occasionally, often, very often, all the
time), 1-6 scale; higher scores represent greater degree of symptoms therefore poorer quality of
life. Average scores in each domain and total average of all scores were used for data analyses.

Willingness-to-pay amount
In accordance with Mitchell and Carson (1981),73 the selected bid amount on the payment scale
was interpreted as an exact expression of the respondent's maximum WTP and treated as a
continuous variable. Mean and median values were calculated on this basis.
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Additional variables
Age, age since dry mouth and monthly expenditure on dry mouth therapies were treated as
continuous variable. A new continuous variable named ‘Years since experiencing dry mouth’
was computed using the difference between respondents’ current age and age since dry mouth;
this new variable was used for all inferential analyses instead of age since dry mouth.
2.6.2 Statistical Analyses

Descriptive statistical analyses were performed to describe the basic features of the collected
data and for descriptive aims. The response rate for paper-based survey was calculated as the
total number of paper-based responses divided by the total number of questionnaires collected
by potential respondents from dental clinics’ front desks. Data summaries, graphs, plots and
cross tabulations were produced for exploring trends in the data. Means/ standard deviation (for
continuous variables) and frequencies/percentages (for categorical variables) were compiled and
are reported in the Section 3.

Independent sample t-tests (t) were carried out to assess differences amongst groups for
continuous variables.
Chi-square tests (χ2) were performed to assess group differences for categorical variables.

Row mean score differ tests (Qs) were used to assess associations between categorical
variables when one variable was on an ordinal (interval) scale, such as association between
levels of satisfaction and etiologies of xerostomia. Furthermore, pairwise comparisons were
carried out to compare each pair of means.
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Spearman's Rank Correlation Coefficient (r) was computed to assess the association between
two continuous variables, or ordinal variables, such as correlation between satisfaction level and
quality of life.
Cronbach’s alpha coefficient (α) was examined to assess internal consistency in each domain
of the quality of life questionnaire, ie. checking whether the items comprising each domain were
reliable. The following commonly accepted values for reliability were used to evaluate the
reliability of the quality of life responses:
Cronbach's alpha

Internal consistency

0.9 ≤ α

Excellent

0.8 ≤ α < 0.9

Good

0.7 ≤ α < 0.8

Acceptable

0.6 ≤ α < 0.7

Questionable

0.5 ≤ α < 0.6

Poor

α < 0.5

Unacceptable

Logistic regression modeling was carried out by regrouping ordinal outcome variable
(willingness to adopt an implantable salivary gland) into dichotomous outcomes. Not at all
willing, not very willing, and somewhat willing were categorized as “low willingness” and very
willing, extremely willing were categorized as “high willingness”. Exclusion of explanatory
variables from the models was considered when inclusion resulted in convergence failure of the
likelihood maximization algorithm.
Demand curves were created using maximum WTP amounts. Demand curves graphically
represent the relationship between the price of a certain commodity and its demand, that is, the
amount of the commodity that consumers are willing to buy at each given price. The curve is
created by adding individual demands at each price level. McIntosh et al.

89

have described a
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procedure to create demand curves using WTP data that we followed to create demand curves
for both WTP outcomes.
All statistical analysis were performed using either Statistical Package for the Social Science
(SPSS), version 20.0.0 for Windows, IBM SPSS Statistics or SAS 9.4 (SAS Institute Inc. Cary,
NC). We used a two-sided alpha level of significance of 0.05.
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3. RESULTS
3.1. Sample results
3.1.1 Response rate
Of 107 total respondents, 63 (58.9%) individuals chose paper-based questionnaire and 44
individuals (41.1%) completed the online survey. A total of 80 paper-based questionnaires were
collected from dental receptions by potential respondents, resulting in a response rate of 78.75%.
A response rate calculation for online surveys could not be performed.
3.1.2 Sample Characteristics
A detailed description of the sample characteristics can be found in Table 4. Education
categories of ‘primary’ and ‘high school’ were merged into ‘high school or less’ due to limited
numbers in these categories. Furthermore, education categories of ‘college’ and university’ were
merged as the survey questionnaire did not specify level of college (such as associate, technical,
etc.). Prostheses categories of ‘dentures’ and ‘partial dentures’ were also combined due to
limited numbers in these categories.
3.1.2.1 Differences in sample characteristics based on mode of survey response
The age of the participants who chose to complete the online survey (M=59.20; SD=9.957) was
significantly lower than those who opted for paper based questionnaires (M=64.43; SD=12.908);
t(107)=2.255, p=0.047. Furthermore, individuals who responded to the online survey had higher
level of education (χ2(2, n=107)=11.431, p=.003) and higher annual household income (χ2(4,
n=96)=25.036, p<.001). Although sample characteristics were different between the two modes
of response, the data from paper questionnaires and online surveys were pooled together for
descriptive analyses.
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3.1.2.2 Association between sample characteristics
Higher education levels were associated with higher levels of annual household income (χ2(8,
n=96)=67.658, p<.001). Respondents who stated having a ‘dental implant with a fake tooth’ had
higher levels of income (χ2(4, n=76)=30.390, p<.001) and higher levels of education (χ2(2,
n=83)=13.656, p=.001) compared to those who stated having a ‘denture or partial denture’.
There were no other significant correlations between the surveyed population characteristics.

Table 4. Surveyed population characteristics
Sex
Male
Female

n

%

52
55

48.6
51.4

Age
Mean (SD): 62.28
(12.014)
Range: 25-89yr
Number of years with dry mouth
(n=104)*
Mean (SD): 9.36 (9.296)
Range: 0-48yr

n

%

Do you have any prosthesis in your mouth?
(n=83)
Denture/partial denture
237
74.8
Dental implant
80
25.2
Education
High school or less
College/University
Graduate level or higher

16
77
14

15.0
71.9
13.1

16
24
20
25
11

15.0
22.4
18.7
23.4
10.3

Income, in 1000 dollars (n=96)
<25
25-50
50-75
75-100
>100

Average monthly expenditure on dry
mouth therapies, in dollars (n=95)
Mean (SD): 49.53
(93.048)
Range: 0-500
n=107, unless specified
* Outlier removed: One respondent stated an overall expenditure of $80,000 for dental
treatments
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3.2 Etiology of Xerostomia and Quality of Life
3.2.1 Etiology of Xerostomia
Of 63 respondents who completed the paper-based questionnaire, 22 individuals checked
multiple etiologies of xerostomia (such as medications and age-related). Therefore, the
etiologies of xerostomia could not be characterized as mutually exclusive categories. The data
was subsequently pooled into three categories for analysis: 1) Sjögren’s syndrome, 2) Radiation,
and 3) Others. Respondents who stated Sjögren’s syndrome, radiation and radioactive iodine for
thyroid cancer as the cause of their Xerostomia did not check any other etiology, therefore, these
categories were considered as mutually exclusive. Categories ‘radiation’ and ‘radioactive iodine
for thyroid cancer’ were merged due to limited number of responses. Table 5a presents the
frequency of each etiology before pooling of categories and Table 5b presents the frequency
after pooling of categories.
Respondents who checked medications listed between 1 to 12 daily medications. The frequency
of listed medications is presented in Table 6 and the combination of medications used by each
respondent is tabulated in Appendix 3. Four out of six individuals who specified other causes
listed the following as the etiology: 1) C-PAP, 2) smoking, 3) high blood pressure, and 4)
removal of salivary glands.
3.2.2 Quality of life
Responses to each question within the four domains (physical functioning, pain/discomfort,
personal/psychological functioning, and social functioning) of the quality of life assessment are
presented in Figures 1-4. Average scores for each domain and total average score were
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calculated for all respondents and ranged between 1 and 6, with higher scores corresponding to
poorer quality of life (Table 7).
Cronbach’s α coefficients revealed excellent internal consistency in the pain/discomfort (α =
.92) and social functioning (α = .92) domains, and good internal consistency in physical
functioning (α = .89) and personal/psychological functioning (α = .83) domains.
3.2.3 Association between etiology of Xerostomia and quality of life
Notably, respondents with ‘Sjögren’s syndrome’ and ‘Radiation’ had significantly higher total
and average domain scores for quality of life when compared to other etiologies, indicating a
poorer quality of life (p≤0.0001). There were no statistically significant differences in quality of
life scores between the ‘Sjögren’s syndrome’ and ‘Radiation’ groups (Table 8).

Figure 1. Quality of life- Physical functioning domain
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Figure 2. Quality of life- Pain/discomfort domain

Figure 3. Quality of life- Personal/psychological functioning domain

Figure 4. Quality of life- Social functioning domain
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Table
5a.
Xerostomia

Etiology

of

n (%)
Sjögren’s syndrome
Diabetes
Medication induced
Radiation
Radioactive Iodine
Age-related
Others
I do not know

13 (12.1%)
10 (9.3%)
30 (28.0%)
8 (7.5%)
1 (0.9%)
11 (10.3%)
6 (5.6%)
50 (46.7%)

Included categories are not mutually
exclusive as several respondents marked
more than one etiology.

Table
5b.
Etiology
of
Xerostomia after pooling of
categories
n (%)
Sjögren’s syndrome
Radiation*
Others

13 (12.1%)
9 (8.4%)
85 (79.5%)

* Includes radiation and radioactive
iodine for thyroid cancer
** Others (Neither Sjögrens Nor
Radiation) includes original categories of
diabetes, medications, age-related,
others, I do not know or a combination
of these categories
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Table 6. Frequency of listed medications, by categories
Adrenergic agent
Antiarrythmic
Anticoagulant
Anticonvulsant

Antidepressant

Antidiabetic
Antifungal
Antihistaminics
Antihypertensives

Cholesterol
DitropanXr
Diuretics

Hormone

Immunosuppresants

Adderall
Vyvanse
Amiodarone
Eliquis
Depakote
Gabapentin
Lamictal
Lamotrigine
Bupropion
Cymbalta
Escitalopram
Lexapro
Prozac
Psychotropic
Quetiapine
Trazadone
Trintellix
Wellbutrin
Metformin
Ketoconasole
Famotidine
Zantac
Atenolol
Benazepril
Clonidine
Lisinopril

n
3
1
2
1
1
1
1
2
1
2
1
1
1
2
1
1
1
1
5
1
1
1
2
1
1
2

Losartan
Fenofibrate
DitropanXr
Hctz
Lasix
Maxide
Spironolactone
Levothyroxine
Synthroid
Yasmin
Hydroxychloroquine
Mercaptopurine
Plaquenil
Simponi

1
1
1
4
1
1
1
1
1
1
1
1
2
1

Minerals &
Vitamins

Muscle
Relaxants
Narcotic
NSAID

Others

Proton pump
inhibitor

Sedative
Statin

Steroids

Calcium500
Caltrate
Coq-10
Ferrex
FolicAcid
Multivitamins
VitaminD
Baclofen
Cyclobenzaprine
Morphine
Oxycodone
Aspirin
FlectorPatch
Meloxicam
Nabumetone
Naproxen
Relafen
Gas-XExtra
Inhalers
Lyrcia
MilkThistle
Myrbetriq
Rapaflo
Sanuvis
Cevimeline
Nexium

n
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

Omeprazole
Protonix
Lunesta
Atorvastatin
Pravastatin
Simvastatin

1
1
1
4
2
4

Androgel
Cortisone
Estradiaol
Fluticasone

1
1
1
1
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Table 7. Quality of life scores, by domain,
Domain

n
(%)

Mean

SD

Median

Physical Functioning
Pain/Discomfort
Personal/Psychological
functioning
Social functioning
Total average Score

107
105
107

3.51
3.55
4.07

1.29
1.15
1.27

3.5
3.4
4

107
107

3.28
3.59

1.41
1.16

3.33
3.53

Table 8. Quality of life scores amongst different etiologies of
Xerostomia
Physical Functioning Domain
Sjögrens
Radiation
Others

n

Mean (SD)

Comparison

p-value

13
9
85

4.77 (0.62)
4.94 (0.53)
3.16 (1.20)

Sjogens vs Radiation
Sjogens vs Others
Radiation vs Others

0.7158
<.0001
<.0001

n

Mean (SD)

Comparison

p-value

13
9
83

4.82 (0.77)
4.93 (0.50)
3.20 (1.00)

Sjogens vs Radiation
Sjogens vs Others
Radiation vs Others

0.7734
<.0001
<.0001

Pain/Discomfort Domain
Sjögrens
Radiation
Others

Personal/psychological Functioning Domain
Sjögrens
Radiation
Others

n

Mean (SD)

Comparison

p-value

13
9
85

5.15 (0.91)
5.35 (0.75)
3.76 (1.19)

Sjogens vs Radiation
Sjogens vs Others
Radiation vs Others

0.6867
<.0001
0.0001

Social Functioning Domain
Sjögrens
Radiation
Others

n

Mean (SD)

Comparison

p-value

13
9
85

4.63 (0.69)
5.00 (0.62)
2.90 (1.29)

Sjogens vs Radiation
Sjogens vs Others
Radiation vs Others

0.4595
<.0001
<.0001
p-value
0. 6285

Total Average Quality of Life
Sjögrens
Radiation
Others

n

Mean (SD)

Comparison

13
9
85

4.83 (0.60)
5.03 (0.53)
3.24 (1.02)

Sjogens vs Radiation
Sjogens vs Others
Radiation vs Others

<.0001
<.0001
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3.3 Satisfaction with Dry Mouth Management strategies
3.3.1 Management strategies
Of the 107 respondents, 106 (99.07%) individuals used water or liquids for management of dry
mouth. However, only 22 individuals (20.56%) relied solely on the latter strategy and commonly
used multiple management strategies. Candies, cough lollies, chewing gums were the second
most commonly (n=72, 67.29%) used strategy. Over the counter medications were used by 42
individuals (39.25%) and 43 respondents (40/19%) also used other strategies. These include:
BioteneTM mouthspray, gels, mouthwashes, prescription drugs including cevimeline and
pilocarpine, TENS, Xyli-MeltTM lozenges, OasisTM dry mouth spray, ora moistTM, orajelTM,
cloves, embalming fluid, coconut oil, herbal medicine, ice, oil pulling, acupuncture, SalivixTM
patch, TherabreathTM, fluoride toothpastes such as Prevident 5000 and non alcoholic
mouthwashes. The frequency of use of these management strategies either alone or in
combination has been presented in Table 9.
3.3.2 Satisfaction with dry mouth management strategies
A majority of the respondents were either moderately or extremely dissatisfied (n=73, 68.32%)
with the therapies that they were currently using (Figure 5). Moderately and extremely satisfied
categories were pooled for further analyses, due to limited numbers.

Figure 5. Satisfaction levels with
currently used dry mouth management
strategies
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3.3.2.1 Association between satisfaction level and etiologies of Xerostomia
Row mean score differ test showed that level of satisfaction with current therapies differed
significantly among different sources of xerostomia (Qs(2, n=107)=9.7867, p=0.0075). Further
pairwise comparisons showed that respondents with ‘Radiation’ associated dry mouth was
significantly different from ‘Others’ group (P=0.0036) in terms of satisfaction level. However,
satisfaction levels between ‘Sjögren’s syndrome’ group when compared to ‘radiation’ (p=
0.0576) and ‘others’ (p=0.183) group was not statistically significant. However, this may be due
to the small sample sizes in Sjögren’s and radiation groups.
3.3.2.2 Association between satisfaction level and dry mouth management strategies
Row mean score differ test showed that level of satisfaction with current therapies differed
significantly between individuals who were using over the counter medications vs. those who
were not (p=0.0007). Satisfaction level was not statistically associated with other management
strategies (Table 10).
3.3.2.3 Association between satisfaction level and quality of life
Spearman correlation test showed a negative correlation between satisfaction level and overall
quality of life (r(105)=-0.546, p<0.001) i.e. the higher XeQOLS score correlated with lower
satisfaction level. Similarly, lower levels of satisfaction were noted with poorer quality of life
in each domain: physical functioning (r(105)=-0.498, p<0.001); pain/discomfort (r(103)=-0.573,
p<0.001); personal/psychological functioning (r(105)=-0.457, p<0.001) and social functioning
(r(105)=-0.506, p<0.001).
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Table 9. Frequency of dry mouth management strategies
Sipping
Water/liqui
ds

Candies,
cough
lollies,
chewing
gums
0
0
0
0
1
1
1
1

Over the
counter
medications

Other

N (%)

0
1
1
1 (0.93)
1
0
0
22 (20.56)
1
0
1
5 (4.67)
1
1
0
7 (6.54)
1
0
0
20 (18.69)
1
0
1
18 (16.82)
1
1
0
15 (14.02)
1
1
1
19 (17.76)
0= No; 1= Yes
E.g. 1,0,1,0 represents individuals who use water/liquids and over the counter
medications (n=7, 6.54%)

Table 10. Association between level of satisfaction and dry mouth
management strategies
Level of Satisfaction (N=107)
Dry Mouth Management
Strategy
Candies, cough lollies,
chewing gums

Over the counter
medications

Other

N

Extremely
dissatisfied

Moderatel
y
dissatisfied

Neutral

Satisfied

0

35

10
28.57

10
28.57

12
34.29

3
8.57

1

72

17
23.61

36
50.00

12
16.67

7
9.72

0

65

10
15.38

27
41.54

20
30.77

8
12.31

1

42

17
40.48

19
45.24

4
9.52

2
4.76

0

64

18
28.13

19
29.69

18
28.13

9
14.06

1

43

9
20.93

27
62.79

6
13.95

1
2.33

P Value*

0.5818

0.0007

0.0906

Cells represents N (%); 0= No, 1=Yes
*From Row Mean Scores Differ test
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3.4. Willingness to adopt and willingness to pay for an implantable salivary gland
pump
3.4.1 Willingness to adopt
A majority of respondents (approx. 55%) were very or extremely willing to adopt an implantable
salivary gland as a new treatment modality. When respondents were asked if they would be
willing to adopt the new treatment modality even if it required “the built-in saliva maker will
need to be changed out in your dentist’s office every year” a majority were still highly willing
to adopt the treatment (Figure 5). The survey respondents were told that this will involve taking
the fake tooth out, removing the built-in saliva maker and putting in a new one.
The willingness to adopt treatment stayed at the same level for nearly 75% respondents (80 out
of 107) when asked about their willingness for treatment with yearly replacements but decreased
for 12 respondents (11.7%). Surprisingly, the level of willingness to adopt treatment with yearly
replacements increased for 15 respondents (14%) from their level of willingness to adopt the
treatment without replacements (Table 11).

Figure 6. Willingness to adopt

an implantable salivary gland
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3.4.2 Willingness-to-pay
Out-of-pocket WTP for a dental implant salivary gland pump ranged from $1,000 to $10,000
for moderate and high-to-complete satisfaction. A total of 83 survey respondents out of 107 were
willing to pay for the new treatment modality with a mean WTP $2,024 if the treatment provided
them with moderate satisfaction. If the treatment provided high-to-complete satisfaction, 84
respondents indicated that they were willing to pay for the treatment modality with a mean WTP
amount of a $2,869 (Table 12). Respondents’ median WTP amounts increased from $1000 to
$2000 when the satisfaction that the treatment could provide increased from moderate to highto-complete satisfaction.
3.4.2.1 Demand Curves
Demand curves for moderate and high-to-complete satisfaction were constructed were
constructed (Figure 6). The X-axes of the demand curves represent the WTP recorded through
this study rather than a uniform scale. These curves represent the percentage of respondents who
are willing to pay for an implantable salivary gland. Almost 60% of individuals were willing to
pay for moderate satisfaction out-of-pocket at a price-point of $1,000. However, at increased
price-points the WTP with moderate satisfaction declined rapidly; only 25% respondents were
willing to pay $2,000. Conversely, at price-points over $4,000 more respondents were willing
to pay if the treatment provided high-to-complete satisfaction compared to moderate
satisfaction. As shown in Table 13, 34 out of 83 respondents (41%) indicated a higher WTP
amount when the satisfaction increased from moderate to high-to-complete satisfaction.
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Figure 7. Demand curves for implantable salivary gland

3.4.3 Association between willingness to adopt new treatment and other variables
Etiology
There was a significant difference in willingness to adopt new treatment between respondents
with different etiologies of Xerostomia (Qs(2)= 12.9507, p=0.0015). Pairwise comparisons
indicated that individuals with xerostomia caused by Sjögren’s syndrome (p=0.0038) and
radiation (p=0.01) had a much higher willingness to adopt this new treatment modality compared
to other etiologies.
Quality of life
Spearman correlation test showed that respondents with a poorer quality of life (higher total
average score) had a higher willingness to adopt an implantable salivary gland (r(105)=0.597,
p<0.0001). Similarly, higher willingness to adopt was noted with higher quality of life average
scores within each domain: physical functioning (r(105)=0.510, p<0.0001); pain/discomfort
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(r(103)=0.612, p<0.0001); personal/psychological functioning (r(105)=0.569, p<0.0001) and
social functioning (r(105)=0.556, p<0.0001).
Satisfaction with dry mouth management strategies
A negative correlation was seen between satisfaction level and willingness to adopt treatment
(r(105)=-0.632, p<0.0001), i.e. respondents who were dissatisfied with the therapies that they
were currently using had a higher willingness to adopt a new treatment modality, namely the
implantable salivary gland.
Willingness-to-pay amounts
Respondents with higher willingness to adopt the new treatment had higher WTP amounts
irrespective of whether they would derive moderate satisfaction (r(81)=0.372, p=0.0005) or
high- to- complete satisfaction (r(82)=0.366, p=0.0007) from the new treatment modality.
Other personal characteristics
There was a weak negative correlation between the respondents age and willingness to adopt the
new treatment (r(105)=-0.225, p=0.0196) indicating that younger people very more likely to
accept an implantable salivary gland. Respondents who have had dry mouth symptoms for a
longer period of time (r(102)=0.295, p=0.0024) and those who spent more money on managing
their dry mouth symptoms (r(94)=0.438, p<0.0001) were more likely to adopt the treatment.
Higher willingness to adopt this new treatment modality was also associated with higher
education (r(105)=0.243, p=0.0118) and income (r(94)=0.371, p=0.0002)levels. In addition,
respondents who had an dental implant had a much higher willingness to adopt the implantable
salivary gland (Qs(1)=7.3204, p=0.0068).
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3.4.4 Association between willingness to pay amounts and other variables
Similar to willingness to adopt new treatment, respondents with an existing dental implant had
a significantly higher willingness-to-pay for an implantable salivary gland, irrespective of
whether they would derive moderate satisfaction (Qs(1)=9.1259, p=0.0025) or high- to complete
satisfaction (Qs(1)=14.8197, p=0.0001).
There was also a significant difference in willingness to pay amounts between respondents with
different etiologies of Xerostomia for moderate (Qs(2)= 7.9017, p=0.0192) and high expected
satisfaction (Qs(2)= 14.8648, p=0.0006) with the new treatment. Pairwise comparisons
indicated that higher willingness to pay for high to complete satisfaction in individuals with
xerostomia caused by Sjögren’s syndrome (p=0.0011) and radiation (p=0.0052) compared to
other etiologies. However, pairwise comparisons for moderate expected satisfaction showed that
the WTP amounts were higher only for respondents within the radiation group (p=0.0097)
compared to others. Sjögren’s syndrome vs. radiation (p=0.4393) and Sjögren’s syndrome vs
other etiologies (p=0.0722) were not significantly associated. No significant correlations were
found between sex or age and willingness to pay (p>0.05). Correlations with other variables are
outlined in Table 14.
3.4.5 Regression analysis for willingness to adopt
As mentioned previously, willingness to adopt new treatment was dichotomized into ‘low’ and
‘high’ willingness for the purpose of building a logistic regression model. Low willingness
includes respondents who stated their willingness as not at all willing / not very willing/
somewhat willing. Individuals who marked Very willing/Extremely willing to adopt the new
treatment were merged into high willingness. Even with this dichotomization of willingness to
adopt new treatment, the bivariate associations between each factor and the outcome variable
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were still maintained. This was demonstrated by logistic regression modeling with each single
factor and is presented in Appendix 4.
We further ran logistic regression analysis with the dichotomous version of willingness-to-adopt
new-treatments. The models included the predictors of quality of life, satisfaction with current
therapy, age, years since starting dry mouth, education (or income). For quality of life, the 4
domain scores and overall score of quality of life were highly correlated and could not be used
simultaneously due to the concern of collinearity. Therefore, we only used the overall average
score of average school in the models. Annual income data collected in this survey was an
ordinal variable with roughly equal intervals between each level, and was therefore, used as a
continuous variable in the model. Due to limitation of this dataset, education and income could
not be included simultaneously in one model due to model converging issue. Table 15 presents
the results from the 2 models that were created. Due to the skewness in WTP data, regression
models were not created for these variables.
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Table 11. Frequency change in willingness to adopt the
implantable salivary gland with yearly replacement
Willing to adopt
new treatment

Willing to adopt new treatment with yearly replacement
Not at
all
willing

Not
very
willing

Somewhat
willing

Very
willing

Extremely
willing

Total

Not at all
willing

9

0

0

0

0

9

Not very
willing

3

5

0

0

0

8

Somewhat
willing

0

3

19

8

1

31

Very willing

0

0

2

19

6

27

Extremely
willing

0

0

0

4

28

32

12

8

21

31

35

107

Frequency

Total

Diagonal cells (Green colored) shows the same level of willingness;
Cells above Diagonal (Blue colored) shows increased level of willingness for Q6;
Cells below Diagonal (Yellow colored) shows decreased level of willingness for
Q6.

Table 12. Mean willingness-to-pay for a dental implant
salivary gland pump

Mean
Standard Error of
Mean
Median

Moderate
Satisfaction

High to complete
satisfaction

2869.04

2024

271.93

214.77

2000

1000

All values are in 2018 USD
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Table 13. Frequency change in willingness-to-pay
amounts between moderate and high satisfaction
WTP_moderate
Frequency

WTP_highsatisfaction
$1,000

$2,000

$4,000

$6,000

$8,000

$10,000

Total

$1,000

34

11

4

1

0

0

50

$2,000

0

10

8

2

0

0

20

$4,000

0

0

1

3

1

0

5

$6,000

0

0

0

2

2

1

5

$8,000

0

0

0

0

0

1

1

$10,000

0

0

0

0

0

2

2

34

21

13

8

3

4

83

Total

Diagonal cells (Green colored) shows the same level of WTP;
Cells above Diagonal (Blue colored) shows increased level of WTP for high to
complete satisfaction;
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Table 14. Associations between WTP amounts and other
variables (Spearman’s Correlations)
WTP amounts for

WTP amounts for

moderate

high to complete

satisfaction

satisfaction

Correlation
N

coefficient

Correlation
N

(r)

coefficient
(r)

Quality of life, by domains
Physical functioning

83

0.387c

84

0.425d

Pain/discomfort

82

0.423d

83

0.504d

Psychological functioning

83

0.357c

84

0.421d

83

0.404c

84

0.435d

83

0.422c

84

0.487d

management strategies

83

-0.261a

83

-0.272a

Willingness to try new treatment

83

0.371c

83

0.366c

with yearly replacements

83

0.498d

83

0.438d

Age

83

Years since Dry Mouth

81

0.296b

81

0.176 (n.s.)

Monthly expenditure

76

0.638d

76

0.302b

Highest Education level

83

0.564d

83

0.570d

Income

78

0.578d

78

0.628d

Social functioning
Quality of life, total average
Level of satisfaction with current

Willingness to try new treatment

-0.076
(n.s.)

83

-0.096
(n.s.)

a

= p < 0.05
= p < 0.01
c
= p<0.001
d
= p<0.0001
n.s.= not significant
b
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Table 15. Bivariate logistic regression analyses of willingness to adopt a
new treatment modality

Quality of life (total
average score)
Satisfaction level with
current therapies
Extremely dissatisfied
Moderately dissatisfied

Model 1
OR (95% CI)
2.197(1.096,
4.405)

p-Value
0.0265

Model 2
OR (95% CI)
2.447 (1.171,
5.114)

0.0177
Ref.

p-Value
0.0174
0.0065

Ref.

0.064 (0.006,
0.642)
0.025 (0.002,
0.317)

0.0195

0.043 (0.003,0.551)

0.0157

0.0065

0.014 (0.001,
0.203)

0.0038

0.0153

0.948 (0.904, 0994)

0.0268

Years since
experiencing dry mouth
Annual household
income

0.93 (0.879,
0.986)
1.077 (1.006,
1.154)
1.508 (0.870,
2.615)

0.0324

1.076 (1.011,
1.145)
N/A

0.0215

Highest education level
High school
College/University

NA
NA
NA

N/A
N/A
N/A

Graduate

NA

N/A

Neutral – Satisfied

Age

0.1430

N/A

0.1645
Ref.
0.451 (0.069,
2.942)
3.783 (0.245,
58.460)

0.4052
0.7982
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4. DISCUSSION
4.1 Summary of research findings
Xerostomia is a widespread problem and can have a significant effect on a patients' quality of
life. The results of this study broadly inform us about patients’ satisfaction and preferences
relating to xerostomia management strategies. This study also elicits individuals willingness-topay for a dental implant based salivary gland pump, which is a product under development by
Dr. J. Robert Kelly and his team. Amongst preference measurement techniques mentioned
previously, the WTP valuation method was chosen over other methods, such as standard gamble
and time-trade-off, since WTP involves a monetary approach to assessing individuals’ perceived
benefits for health care interventions.74, 89-91 This makes the resulting WTP values directly
comparable to the costs of the treatment. Moreover, the methodology used for this WTP survey
simulates real-world decision-making situations, in which people in a privately financed oral
health care industry are bound to incorporate economic considerations in their final decision
towards dental treatments.
Our results show that dry mouth itself, irrespective of its etiology, and patients’ satisfaction with
currently available management strategies are highly associated with compromised oral health
related quality of life. Furthermore, individuals with Sjögren’s syndrome and a history of
radiation appear to have an overall worse quality of life and lower satisfaction with management
strategies. Several studies 92-99 have previously looked into Xerostomia related quality of life in
these two groups of patients and found similar compromised quality of life as seen in our study.
However, to the author’s knowledge, associations between satisfaction with therapies in use and
quality of life have not been previously reported.
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The dry mouth management strategies reported by respondents of this survey are similar to those
reported in other studies

17, 100-102

,and included drinking water and liquids, sucking on ice,

candies and cough lollies, chewing gums, prescription medications like pilocarpine and
cevimeline and over the counter products including BioteneTM mouthspray, BioteneTM gels,
BioteneTM mouthwashes, Xyli-MeltTM lozenges, OasisTM dry mouth spray, ora moistTM, orajelTM,
SalivixTM patch, TherabreathTM, fluoride toothpastes such as Prevident 5000 and non-alcoholic
mouthwashes as well as alternative non-pharmacological therapies including keeping cloves in their
mouth, transcutaneous electrical nerve stimulation (TENS), embalming fluid, coconut oil, herbal
medicine, oil pulling (an Ayurvedic technique that involves swishing oil in the mouth) and
acupuncture. Notably, most of the respondents were not satisfied with the strategies that they

were currently using. The association of satisfaction with current therapies and quality of life is
in accordance with our expectations that those with a lower satisfaction level would have a
poorer quality of life.
In this study, oral health related quality of life was assessed using a modified version of
University of Michigan Xerostomia-Related Quality of Life Scale (XeQOLS). Four domains,
namely, physical functioning, personal/psychological functioning, social functioning and
pain/discomfort issues were characterized based on the reference XeQOLS and clinical experience.
Average data for each of these domains suggests that personal/psychological functioning of
respondents was affected the most, followed by pain and discomfort, physical functioning, and social
functioning. In addition, a more comprehensive view of the effect of xerostomia can be obtained by
studying each of the items within these domains. For instance, even though physical functioning was
overall less affected by xerostomia, a majority (56%) of respondents stated that dry mouth made it
difficult to speak to others ‘all the time’, which was a question within the same domain. Similarly,
nearly 60% individuals indicated that dry mouth negatively affected their intimate relations ‘often’,
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‘very often’ or ‘all the time’, even though the overall domain of social functioning had the lowest
average score.

Several medications have been implicated as the cause of xerostomia 8, 17, however, there are no
epidemiological studies investigating the patterns of medication use and presence of xerostomia.
Our survey data shows similar categories of medications used by respondents who were aware
that their xerostomia was caused by medication use. However, this data is descriptive in nature
and cannot inform an inferential association. There may be several other individuals on multiple
medications who responded to this survey and were not aware of the relation between
medications and dry mouth.
Our findings reveal that respondents’ willingness to adopt the new treatment modality of an
implantable salivary gland were in accordance of our expectations: individuals with poorer selfperceived oral health related quality of life, lower satisfaction with current therapies that they
were using and the longer that they had been experiencing dry mouth symptoms were more
likely to adopt the treatment. As has been stated in the literature, the experience of the illness
shapes the preferences of an individual towards a certain treatment.83 Various WTP studies have
also reported a positive relationship between an increased likelihood of disease with higher WTP
amounts.103, 104 In our study, people with poorer quality of life and low satisfaction level, which
is an indicator of perceived need, had higher willingness to adopt and higher WTP for the
implantable salivary gland.
Interestingly, for nearly three-quarters of the respondents, the willingness to adopt this treatment
was not influenced when an additional yearly replacement was added to the scenario. This may
be due to the respondents’ knowledge of the need for recurrent treatments for certain medical
conditions or their need for improved management irrespective of the nuances of the treatment
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involved. There is also a chance that this may be due to a lack of clear understanding of the
scenario presented in the survey questionnaire even though we piloted the survey for construct
validity.
Our findings also show that respondents who have an existing dental implant were more likely
to adopt the implantable salivary gland pump treatment and also had a higher willingness-to-pay
for the treatment modality. This echoes findings in the literature that consumers’ individual
preferences can be shaped by their previous knowledge about the benefits of a certain
commodity.91, 103, 105 Positive experience and knowledge are expected to yield higher preference
values.

4.2 Limitations
The primary outcomes for this study included respondents’ willingness to adopt and willingnessto-pay for a new treatment modality. Such evaluations face substantial issues with sample size
calculations due to lack of guidance on an acceptable value for standard error around the mean
value.106 In addition, without any a priori information, estimation of a confidence interval is also
unattainable. Due to these issues, the sample for most ‘preference assessment’ studies relies on
maximum achievable with available resources.106 Similarly, our calculation of 100 potential
respondents was based on time limitations.
Convenience sampling, as employed in our data collection, is subject to sampling bias that may
compromise the accuracy of the results as the included sample is not representative of the entire
population. It can create substantial issues when responders to the survey are significantly
different than the non-respondents.106 Since our survey study was primarily conducted through
volunteer survey responses, there was no possibility of assessing the characteristics of nonrespondents. In addition, our survey was advertised primarily in the dental clinics and TV
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monitors of a hospital setting, which limited in terms of its reach to a representative population.
This can be noted in the distribution of etiologies of the Xerostomia population, education and
income categories.
There are other potential biases associated with ‘preference assessment’ methodologies for a
commodity or healthcare intervention that may have also affected our survey-based study. These
can be broadly divided into three main groups: 1) construction of a hypothetical market, 2)
survey administration, and 3) interpretation of the data. While a detailed description of all these
potential issues is beyond the scope of this dissertation, those pertinent are discussed here.
There are two biases, namely hypothetical bias and strategic bias, associated with construction
of a hypothetical market, which in our study is the implantable salivary gland. Hypothetical bias
occurs when respondents’ stated intentions, (i.e, willingness to adopt or willingness to pay for a
treatment) deviate from actual behaviors.107 This has been evidenced recently in assessments of
individuals’ real buying behavior, where preference assessment studies systematically
overestimated the stated buying behavior.108 Recommendations to minimize hypothetical bias
include creating a scenario with as “real-life” a situation as possible. To ensure this, we modified
our questions in the survey assessing patients’ willingness to adopt and willingness to pay based
on guidance provided by our pilot study respondents during construct validation.
Strategic bias occurs when respondents deliberately over- or understate their preferences to
influence the implantation of a service or a product. 79, 107 This is a significant problem in
environmental and transport-related preference measurement studies, however, do not affect
healthcare preference assessments as much.107 We did not suspect strategic bias to be a potential
issue in our study, as the use of payment cards for WTP restricted the responses, as compared
to open-ended questions. 80, 107
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5. CONCLUSIONS
Individuals experiencing xerostomia are largely dissatisfied with currently available dry mouth
management strategies. The condition itself and low satisfaction with available therapies
negatively affect their oral health related quality of life. Within the limitations of this study, the
data suggests that people living with xerostomia would substantially value a dental implant
based implantable salivary gland that would periodically release artificial saliva into the mouth.
Therefore, stakeholders in this product development can use this study information to determine
the desirability and implementation of this product.
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Dry Mouth Treatments
We are asking you to take part in this research survey because you have been diagnosed with dry mouth
(xerostomia). The title of this study is “Patients’ satisfaction with existing dry mouth therapies and willingness
to pay for an artificial salivary gland” and the Principal Investigator for this study is Dr. Robert J. Kelly. This
research is being carried out as part of a project required for a master’s degree in dental science for Dr.
Akanksha Srivastava, who is a third year resident at University Of Connecticut School of Dental Medicine
Graduate Prosthodontics program.
We are conducting this survey to better understand how satisfied are people with existing therapies and how
willing they would be to adopt a new treatment for dry mouth. This survey consists of 4 sections (total 4 pages
including this letter). In the first section you will be asked about the cause(s) of your dry mouth, if known and
its effect on your oral and general health. In the second section, you will be asked about any
treatment/medications that you have tried for your dry mouth and how satisfied you are with each of the
therapies. In the third section, you will be provided information about a new treatment modality and asked to
indicate your willingness to adopt this treatment. This section will also include two cost situations, and you will
be asked your opinion about each. At the end, you will be asked to provide some personal information (e.g.
your age, education, etc.). Completing the survey should take only about 10 minutes.
You have the option to respond to this paper-based questionnaire and return it to the receptionist in the
envelope that has been provided to you. Alternatively, you may complete the same survey on the internet at
the following web-link: https://www.surveymonkey.com/r/VBYXVV7
The principal investigator, Dr. Robert Kelly, in an inventor of the new treatment modality that we are asking
you questions about. For this treatment, a patent may be filed by the institution. If the patent is pursued, based
on data from this and other research, royalties and other compensation may be received by the institution and
the investigator. Thus, the principal investigator has a financial interest in the outcome of this study.
Your participation is voluntary and you have the right to discontinue the survey at any time or skip any questions
that make you uncomfortable. Your choice to not participate in the study will not affect any health care services
that you are receiving or for which you would otherwise be eligible. Participation in the survey implies consent
for the study team to use your responses for the study described above. There are no foreseeable risks from
participating in this study. All of your responses are confidential and anonymous. Please do not provide your
name anywhere in the survey or on the return envelope. For any enquiries about the questionnaire, please feel
free to contact the survey coordinator, Dr. Akanksha Srivastava (at aksrivastava@uchc.edu or 860-679-1873).
If you have questions about your rights as a research subject you may contact a coordinator at the UConn Health
Centre Institution Review Board at 860-679-1019, 860-679-4851, or 860-679-4849.
Thank you again for your participation.
Sincerely,
Dr. Akanksha Srivastava (Resident)
Dr. Robert J. Kelly (Principal Investigator)
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I. DRY MOUTH: CAUSE AND ITS EFFECT ON YOUR ORAL AND GENERAL HEALTH
1) Please indicate the cause of your dry mouth by checking the appropriate box below:

Sjögren’s syndrome

Diabetes

Medication induced, if so please specify name(s) of medications ___________________
______________________________________________________________________________

Radiation induced

Radioactive iodine for thyroid cancer

Age-related

Other, if so please specify___________________________________________________

I do not know
2) Please check ONE of the answers for each of the following questions
Neve
Rarel
My dry mouth…
r

y

Occasion

Ofte

Very

All

ally

n

often

the
time

i.

Restricts the amount and type of food I eat













ii.

Gives me an uncomfortable feeling in my mouth













iii.

Makes me worry













iv.

Restricts my social life













v.

Makes it awkward to eat in front of other people













vi.

Makes it difficult to speak to other people













vii.

makes me nervous













viii.

Is the cause of considerable tension













Makes me worry about the look of my teeth and













ix.

mouth
x.

Makes me feel depressed













xi.

Restricts me in my daily activities













xii.

Negatively affects my intimate relations













xiii.

Changes the taste of food













xiv.

Makes me worry about cavities in my teeth.













xv.

Makes me worry about fungal infections/sores in













my mouth.
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II. SATISFACTION WITH CURRENT THERAPY
3) Do you use any of the following to help with your dry mouth (Mark all that apply)
 Sipping water/liquids
 Candies, cough lollies, chewing gums
 Over the counter medications

Other, please specify _____________________
4) How satisfied are you with the remedies you are currently using?


Extremely
dissatisfied



Moderately
dissatisfied



Neutral



Moderately
satisfied



Extremely
satisfied

III. WOULD YOU TRY A NEW TREATMENT FOR DRY MOUTH?
Please consider the following:
A dental implant is a metal post that is placed in your jaw bone under your
gums with a fake tooth over it as shown in the picture.
To place the implant, a small surgery is done under local anesthesia
(novocaine). Minor discomfort and pain is expected for 1day-1week and
managed with pain medications, if needed. Once the implant is completely
healed in the bone (approx. 2-3 months), a fake tooth is screwed in to the
implant.
5). How likely would you be willing to try a new treatment for your dry mouth if it involves placing a
dental implant with a built-in artificial saliva maker in your upper or lower jaw? Please select one.

 Not at all
 Not very
 Somewhat
 Very
 Extremely
willing
willing
willing
willing
willing
6) How likely would you be willing to try this new treatment if the built-in saliva
maker will need to be changed out in your dentist’s office every year? This will
involve taking only the fake tooth out, which will allow removal of the built-in saliva
 Not at all
 Not very
 Somewhat
 Very
 Extremely willing
willing
willing
willing
willing
maker to be able to put in a new one. This will be a painless, non-surgical procedure.
Please select one.
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7) How much money out-of-pocket is it worth to you to get this dental implant with the
built in saliva maker if it will provide you with moderate satisfaction? Please note that the
yearly recurring costs of replacing the built-in saliva maker will be $500/year. Choose the
largest amount on the right you would be willing to pay for this treatment out-of-pocket.
Please select only ONE.








$1,000
$2,000
$4,000
$6,000
$8,000
$10,000

8) How much money out-of-pocket is it worth to you to get this dental implant with the
built in saliva maker if it will provide you with high to complete satisfaction? Please note
that the yearly recurring costs of replacing the built-in saliva maker will be $500/year.
Choose the largest amount on the right you would be willing to pay for this treatment outof-pocket. Please select only ONE.








$1,000
$2,000
$4,000
$6,000
$8,000
$10,000

IV. PERSONAL INFORMATION
Please indicate the following about yourself. Once again be assured that the information you provide
is confidential and anonymous.
9)
Sex

 Female

 Male

10) How old are you?________________
11) How old were you when you started experiencing dry mouth? ____________
12) How much do you spend per month, on average, on treating dry mouth? _______________
13) Do you have any of these in your mouth?
 Denture
 A flipper (also called a partial denture)

 Dental implant with a fake tooth

14) What is your highest level of education attained? Please select one.

Primary school

University degree

High school

Graduate University degree or higher

CEGEP/ college

I prefer not to answer
15) Please tell us your annual household income (before taxes and insurance payments). Include your
own income and of your spouse/partner. Please select one.

Less than $25,000

$75,000 to $100,000

$25,000 to $50,000

More than $100,000

$50,000 to $75,000

I prefer not to answer
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Appendix 2- Research Flyer
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Appendix 3- Medications listed by each respondent
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Medications

Frequen
cy
(total=3
0)

Atorvastatin, Hydroxychloroquine, Ferrex, Escitalopram Oxalate, Gas-X Extra,
Apirin, Folic Acid, Spironolactone

1

Cortisone

1

Famotidine, Metformin, Fenofibrate, Benazepril

1

HCTZ, Trazadone, Gabapentin, Singulair, Metoprolol

1

Lipitor, Lisinopril, Morphine, Meloxicam, Myrbetriq, Rapaflo, Baclofen, Xarelto,
Metopril, Androgel, Ketoconasole, Flector Patch

1

Lipitor, Propronolol

1

Metformin, Simvastatin, Sanuviz

1

Metformin, Pravastatin, Metoprolol, Hctz

1

Metoprolol, HCTZ, Lexapro, Lunesta, Protomix, Lyrcia, Estradiaol, Eliquis

1

Metoprolol, HCTZ, Simvastatin, Adderall

1

Milk Thistle, Levothyroxine, Caltrate, Oxycodone, Mercaptopurine, Norvasc

1

Omeprazole, Fluticasone, Coq-10, Atorvastatin, Multivitamins, Lasix, Losartan,
Calcium 500, Naproxen

1

Plaquenil, Nabumetone, Synthroid

1

Pravastatin

1

Psychotropic Meds, Cymbalta, Lamictal, Proazasin, Quetiapine, Clonidine

1

Psychotropic, Inhalers

1

Ralaphen, Plequinil

1

Simponi, Wellbutrin, Yasmin, Adderall, Cevimeline, Acyclovir

1

Simvastatin

1

Trintellix, Bupropion, Vyvanse

1

Xyrem, Ditropan Xr, Atenolol, Cymbalta, Prozac, Maxide

1

Alprazolam, Alendronate

1

Amlodipine, Lisinipril

1

Cyclobenzaprine, Zantac, Vitamin D, Nexium

1

Depakote, Adderrall, Lamotrigine, Atenolol, Propranolol

1
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Metformin

2

Simvastatin, Amiodarone, Multivitamins, Lamotrigine

1

* One respondent did not specify any medications and stated ‘A lot of medicines’ as
the response
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Appendix 4- Bivariate associations between outcome and explanatory
variables from logistic regression modeling
(as discussed in Section 3.4.5)
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Type 3 Analysis of Effects

Effect

D
F

Wald
ChiSquare

Pr > ChiS
q

Q1_Cause

2

8.3057

0.0157

Type 3 Analysis of Effects

Effect

D
F

Wald
ChiSquare

Pr > ChiS
q

q9_sex

1

0.4227

0.5156

Type 3 Analysis of Effects

Effect

D
F

Wald
ChiSquare

Edu_3C

2

6.1047

Pr > ChiS
q
0.0472

Type 3 Analysis of Effects

Effect
Satisfy_C
3

D
F

Wald
ChiSquare

Pr > ChiS
q

2

23.2563

<.0001
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Analysis of Maximum Likelihood Estimates

Parameter

D
F

Estima
te

Standa
rd
Error

Wald
ChiSquare

Pr > ChiS
q

Intercept

1

1.4457

0.5555

6.7722

0.0093

q15_annualinco
me

1

0.5962

0.1829

10.6222

0.0011

Analysis of Maximum Likelihood Estimates

Parameter

D
F

Estima
te

Standa
rd
Error

Wald
ChiSquare

Pr > ChiS
q

Intercept

1

3.9639

0.8707

20.7266

<.0001

q2_total_Avg

1

1.1867

0.2428

23.8956

<.0001

Analysis of Maximum Likelihood Estimates
Standa
rd
Error

Wald
ChiSquare

Pr > ChiS
q

Parameter

D
F

Estima
te

Intercept

1

2.4111

1.1178

4.6523

0.0310

q10_age

1

0.0352

0.0175

4.0584

0.0440

Analysis of Maximum Likelihood Estimates

Parameter

D
F

Estima
te

Standa
rd
Error

Wald
ChiSquare

Pr > ChiS
q

Intercept

1

0.3709

0.3102

1.4301

0.2317

Year_DryMouth

1

0.0753

0.0306

6.0555

0.0139
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